ultra-fast-amplicon-based-next-generation-sequencing-non-squamous-non

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

The number of molecular alterations to be tested for targeted therapy of non-squamous non-small cell lung cancer (NS-NSCLC) patients has significantly ...

Université Côte d'Azur, Hôpital Pasteur, CHU de Nice

Université Côte d'Azur

Chronic obstructive pulmonary disease (COPD) is a common condition that may initially look simple but may conceal other diseases capable of accelerating its natural history or even simulating it. We describe four cases presenting as COPD with emphysema that were reclassified on the basis of certain clinical characteristics and the radiological pattern.

[Emphysema, did you say emphysema?].

: With the integration of various targeted therapies into the clinical management of patients with advanced lung adenocarcinoma, next-generation sequencing (NGS) has become the technology of choice and has led to an increase in simultaneously interrogated genes. However, the broader adoption of NGS for routine clinical practice is still hampered by sophisticated workflows, complex bioinformatics analysis and medical interpretation. Therefore, the performance of the novel QIAGEN GeneReader NGS system was compared to an in-house ISO-15189 certified Ion PGM NGS platform. : Clinical samples from 90 patients (60 Retrospectively and 30 Prospectively) with lung adenocarcinoma were sequenced with both systems. Mutations were analyzed and , , , , ,  and  genes were compared and sampling time and suitability for clinical testing were assessed. : Both sequencing systems showed perfect concordance for the overlapping genes. Correlation of allele frequency was ² = 0.93 for the retrospective patients and ² = 0.81 for the prospective patients. Hands-on time and total run time were shorter using the PGM system, while the GeneReader platform provided good traceability and up-to-date interpretation of the results. : We demonstrated the suitability of the GeneReader NGS system in routine practice in a clinical pathology laboratory setting.

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients.

Early-stage treatment improves prognosis of lung cancer and two large randomized controlled trials have shown that early detection with low-dose computed tomography (LDCT) reduces mortality. Despite this, lung cancer screening (LCS) remains challenging. In the context of a global shortage of radiologists, the high rate of false-positive LDCT results in overloading of existing lung cancer clinics and multidisciplinary teams. Thus, to provide patients with earlier access to life-saving surgical interventions, there is an urgent need to improve LDCT-based LCS and especially to reduce the false-positive rate that plagues the current detection technology. In this context, LCS can be improved in three ways: (1) by refining selection criteria (risk factor assessment), (2) by using Computer Aided Diagnosis (CAD) to make it easier to interpret chest CTs, and (3) by using biological blood signatures for early cancer detection, to both spot the optimal target population and help classify lung nodules. These three main ways of improving LCS are discussed in this review.

Lung Cancer Screening, Towards a Multidimensional Approach: Why and How?

[Pseudo tumor lesions induced by infectious agents. Case no. 3].

[Pseudo-tumor lesions induced by infectious agents. Case No. 4].

[Pseudo-tumor lesions induced by infectious agents. Case no. 7].

[Pseudo-tumor lesions induced by infectious agents. Case no. 8].

[Pseudo tumor lesions induced by infectious agents. Case n°6].

[Pseudotumor lesions induced by infectious agents. Case n 5].

Early-stage lung cancer, primarily treated with surgery, often occur in poor surgical candidates (impaired respiratory function, prior thoracic surgery, severe comorbidities). Stereotactic ablative radiotherapy (SABR) is a non-invasive alternative that provides comparable local control. This technique is particularly relevant for surgically resectable metachronous lung cancer, in patients unable to undergo surgery.. The objective of this study is to evaluate the clinical outcome of patients treated with SABR for stage I metachronous lung cancer (MLC) versus stage I primary lung cancer (PLC).

Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer.

Several therapies to improve the management of lymphoma are currently being investigated, necessitating the development of new biomarkers. However, this requires high-quality and clinically annotated biological material. Therefore, we established a lymphoma biobank including all available biological material (tissue specimens and matched biological resources) along with associated clinical data for lymphoma patients diagnosed, according to the WHO classification, between 2005 and 2022 in the Laboratory of Clinical and Experimental Pathology, Nice, France. We retrospectively included selected cases in a new collection at the Côte d'Azur Biobank, which contains 2150 samples from 363 cases (351 patients). The male/female ratio was 1.3, and the median age at diagnosis was 58 years. The most common lymphoma types were classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and extra-nodal marginal zone lymphoma of MALT tissue. The main sites of lymphoma were the mediastinum, lymph node, Waldeyer's ring, and lung. The Côte d'Azur Biobank is ISO 9001 and ISO 20387 certified and aims to provide high quality and diverse biological material to support translational research projects into lymphoma. The clinico-pathological data generated by this collection should aid the development of new biomarkers to enhance the survival of patients with lymphoid malignancies.

The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France).

Article	Year
[Emphysema, did you say emphysema?]. Revue des maladies respiratoires\| PubMed ID: 29402641	2018
Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment ... Cancers\| PubMed ID: 29561830	2018
Lung Cancer Screening, Towards a Multidimensional Approach: Why and How? Cancers\| PubMed ID: 30759893	2019
[Pseudo tumor lesions induced by infectious agents. Case no. 3]. Annales de pathologie\| PubMed ID: 31010595	2019
[Pseudo-tumor lesions induced by infectious agents. Case No. 4]. Annales de pathologie\| PubMed ID: 31104854	2019
[Pseudo-tumor lesions induced by infectious agents. Case no. 7]. Annales de pathologie\| PubMed ID: 31255413	2019
[Pseudo-tumor lesions induced by infectious agents. Case no. 8]. Annales de pathologie\| PubMed ID: 31255414	2019
[Pseudo tumor lesions induced by infectious agents. Case n°6]. Annales de pathologie\| PubMed ID: 31301879	2019
[Pseudotumor lesions induced by infectious agents. Case n 5]. Annales de pathologie\| PubMed ID: 31303345	2019
Comparison of outcome after stereotactic ablative radiotherapy of patients with metachronous lung versus primary lung cancer. Radiation oncology (London, England)\| PubMed ID: 37287020	2023
The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France). Journal of personalized medicine\| PubMed ID: 37511690	2023

Jonathan Benzaquen

Biography

JoVE Journal Publications

Other Publications